Vaborbactam (1 brand name, 1 dosage form, 1 route)
Available dosage forms: POWDER.
Routes of administration: INTRAVENOUS.
Brand Names
- VABOMERE
Contraindications
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs [see Warnings and Precautions (5.1)].
Adverse Reactions
The following adverse reactions are discussed in greater detail in the Warnings and Precautions section: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizure Potential [see Warnings and Precautions (5.2)] Rhabdomyolysis [see Warnings and Precautions (5.3)] Clostridioides difficile-associated Diarrhea [see Warnings and Precautions (5.4)] Risk of Breakthrough Seizures Due to Drug Interaction with Valproic Acid [see Warnings and Precautions (5.5)] Thrombocytopenia [see Warnings and Precautions (5.6)] Potential for Neuromotor Impairment [see Warnings and Precautions (5.7)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.8)] Overgrowth of Non-susceptible Organisms [see Warnings and Precautions (5.9)]
Mechanism of Action
VABOMERE is an antibacterial drug [see Microbiology (12.4)].
Overdosage
In the event of overdose, discontinue VABOMERE and institute general supportive treatment. Meropenem and vaborbactam can be removed by hemodialysis. In subjects with end-stage renal disease (ESRD) administered meropenem 1 gram and vaborbactam 1 gram, the mean total recovery in dialysate following a hemodialysis session was 38% and 53% of the administered dose of meropenem and vaborbactam, respectively. No clinical information is available on the use of hemodialysis to treat VABOMERE overdosage.